D-0853-2026 Class II Ongoing

Recalled by Pfizer — Manhattan, NY

FDA drug recall D-0853-2026 was initiated by Pfizer on Sep 4, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Sep 23, 2026
Initiation Date
Sep 4, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

US Nationwide.

Code information

Lot # NL5230, Exp Date:10/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0853-2026
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0853-2026. Report a data issue: hello@regdatalab.com.